Advertisement
Research ArticleArticle

SB 207499 (Ariflo), a Second Generation Phosphodiesterase 4 Inhibitor, Reduces Tumor Necrosis Factor α and Interleukin-4 Production in vivo

Don E. Griswold, Edward F. Webb, Alison M. Badger, Peter D. Gorycki, Patricia A. Levandoski, Mary A. Barnette, Marilyn Grous, Siegfried Christensen and Theodore J. Torphy
Journal of Pharmacology and Experimental Therapeutics November 1998, 287 (2) 705-711;
Submit a Response to This Article
Compose eLetter

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Statement of Competing Interests

Vertical Tabs

Jump to comment:

No eLetters have been published for this article.
Back to top

In this issue

Download PDF
Article Alerts
Email Article
Citation Tools
Research ArticleArticle

SB 207499 (Ariflo), a Second Generation Phosphodiesterase 4 Inhibitor, Reduces Tumor Necrosis Factor α and Interleukin-4 Production in vivo

Don E. Griswold, Edward F. Webb, Alison M. Badger, Peter D. Gorycki, Patricia A. Levandoski, Mary A. Barnette, Marilyn Grous, Siegfried Christensen and Theodore J. Torphy
Journal of Pharmacology and Experimental Therapeutics November 1, 1998, 287 (2) 705-711;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo

Jump to section